Mou Minjie, Zhang Yintao, Qian Yuntao, Zhou Zhimeng, Liao Yang, Niu Tianle, Hu Wei, Chen Yuanhao, Jiang Ruoyu, Zhao Hongping, Dai Haibin, Zhang Yang, Fu Tingting
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, China.
J Pharm Anal. 2025 Jun;15(6):101298. doi: 10.1016/j.jpha.2025.101298. Epub 2025 Apr 9.
Advancements in artificial intelligence (AI) and emerging technologies are rapidly expanding the exploration of chemical space, facilitating innovative drug discovery. However, the transformation of novel compounds into safe and effective drugs remains a lengthy, high-risk, and costly process. Comprehensive early-stage evaluation is essential for reducing costs and improving the success rate of drug development. Despite this need, no comprehensive tool currently supports systematic evaluation and efficient screening. Here, we present druglikeFilter, a deep learning-based framework designed to assess drug-likeness across four critical dimensions: 1) physicochemical rule evaluated by systematic determination, 2) toxicity alert investigated from multiple perspectives, 3) binding affinity measured by dual-path analysis, and 4) compound synthesizability assessed by retro-route prediction. By enabling automated, multidimensional filtering of compound libraries, druglikeFilter not only streamlines the drug development process but also plays a crucial role in advancing research efforts towards viable drug candidates, which can be freely accessed at https://idrblab.org/drugfilter/.
人工智能(AI)和新兴技术的进步正在迅速拓展对化学空间的探索,推动创新药物的发现。然而,将新型化合物转化为安全有效的药物仍然是一个漫长、高风险且成本高昂的过程。全面的早期评估对于降低成本和提高药物开发成功率至关重要。尽管有此需求,但目前尚无全面的工具支持系统评估和高效筛选。在此,我们展示了druglikeFilter,这是一个基于深度学习的框架,旨在从四个关键维度评估类药性:1)通过系统测定评估的物理化学规则;2)从多个角度研究的毒性警示;3)通过双路径分析测量的结合亲和力;4)通过逆合成路线预测评估的化合物可合成性。通过实现对化合物库的自动化、多维度筛选,druglikeFilter不仅简化了药物开发过程,还在推进对可行药物候选物的研究工作中发挥着关键作用,可在https://idrblab.org/drugfilter/免费获取。